Deloitte January 9, 2024

Explore our 2024 life sciences M&A predictions

Life sciences M&A was a bright spot across the wider dealmaking world in 2023. Will this positive trend continue over the next 12 months? We think so. We’re making five bold 2024 life sciences M&A predictions, which include another strong year for pharma M&A and a positive turn for the MedTech market. Find out what...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more

Share This Article